Skip to main content

EHA2023 Hybrid Congress

23-06-2023 Multiple Myeloma News

Cilta-cel improves outcomes in lenalidomide-refractory multiple myeloma

Treatment with ciltacabtagene autoleucel significantly extends progression-free survival relative to standard of care in people with lenalidomide-refractory multiple myeloma who have received up to three prior lines of therapy.

No radiotherapy required for patients with PMBCL in remission

22-06-2023 Non-Hodgkin Lymphoma News

The IELSG37 study provides robust evidence that radiotherapy can be omitted in patients with primary mediastinal B cell lymphoma who have achieved a complete metabolic response with dose-intensive immunochemotherapy.

Relapsed and refractory PTCL treatments mapped

22-06-2023 Non-Hodgkin Lymphoma News

Dutch population-based research provides insight into the most commonly used treatment strategies for people with relapsed and refractory peripheral T-cell lymphoma.

Risk of diabetes in hemochromatosis C282Y homozygotes

22-06-2023 Hematology News

Hemochromatosis C282Y homozygotes have an increased risk of diabetes even if they have normal levels of iron, transferrin saturation or ferritin. Current treatment, which focuses on lowering ferritin, may not adequately reduce the risk of diabetes.

Outcomes and safety of axicabtagene ciloleucel

22-06-2023 Non-Hodgkin Lymphoma News

The outcomes and safety of axicabtagene ciloleucel in patients with relapsing or refractory follicular lymphoma appear to be consistent with the outcomes and safety observed in the ZUMA-5 study in daily practice.

Unlock your free access to coverage of the EHA2023 Hybrid Congress Coverage

Ruxolitinib is effective in myelofibrosis regardless of anemia and transfusion status

22-06-2023 Primary Myelofibrosis News

Ruxolitinib improves spleen volume and total symptom score in patients with myelofibrosis regardless of anemia and transfusion status at baseline. This is evident from a post hoc analysis of the two COMFORT studies.

Romiplostim plus ciclosporin A in patients with aplastic anemia

22-06-2023 Aplastic Anemia News

Romiplostim combined with ciclosporin A could serve as a new first-line treatment for patients with aplastic anemia. This is the conclusion of Japanese researchers based on phase II/III results.

Prognosis in R/R diffuse large cell B-cell lymphoma

A Dutch population study shows that survival of patients with early relapsing/refractory diffuse large cell B cell lymphoma treated with second-line intensive therapy with or without autologous stem cell transplantation is downright poor.

Exa-cel: Cure for patients with transfusion-dependent β-thalassemia

21-06-2023 Thalassemia News

Interim results of the CLIMB THAL-111 study show that exagamglogene autotemcel has the potential to cure patients with transfusion-dependent β-thalassemia with a single treatment.

'Paradigm shift’ for anemia associated with lower-risk MDS

Luspatercept almost doubles the likelihood of achieving transfusion independence with hemoglobin increase relative to epoetin alfa in ESA-naïve patients with anemia due to lower-risk myelodysplastic syndromes.

Baseline protein profiles can predict MRD status in CLL

The HOVON 141/VISION study shows that protein profiles at baseline in patients with chronic lymphocytic leukemia are predictive of MRD status after 15 months of treatment with venetoclax plus ibrutinib.

Pacritinib as pretreatment allo-SCT in myelofibrosis

Treatment with pacritinib is a safe and effective pretransplantation strategy for patients with myelofibrosis. This emerges from the final analysis of the phase II HOVON134 trial.

Ziftomenib promising for relapsed or refractory NPM1-mutated AML

19-06-2023 Acute Myeloid Leukemia News

Ziftomenib has demonstrated encouraging clinical activity and manageable safety in people with relapsed or refractory acute myeloid leukemia carrying NPM1 mutations in the early-phase KOMET-001 trial.

Fixed-duration venetoclax–obinutuzumab provides sustained benefit in CLL

The 6-year results from the CLL14 study confirm the long-term benefits of a 1-year regimen of venetoclax plus obinutuzumab in previously untreated patients with chronic lymphocytic leukemia and co-existing conditions.

Stay up to date with more from Springer Medicine

Keynote webinar | Spotlight on cardio-oncology

Webinar | 16-05-2023 | 17:30 (CEST)

An expert-led symposium exploring the most pertinent issues in cardio-oncology, with a focus on the new ESC guidelines. Highlights include preventative approaches in cardio-oncology, toxicity risk-stratification strategies, the clinical management of myocarditis as an adverse effect of immune checkpoint inhibitor-treatments, and the utility of biomarkers in long-term follow-up of cardiovascular disease risk in cancer patients.

Prof. Rudolf de Boer
Prof. Lorenz Lehmann
Dr. Teresa Lopéz Fernández
Developed by: Springer Medicine

Episode 2: Progress in PARP inhibitors

In this episode, Dr. Elena Castro takes us through the latest evidence for PARP inhibitors and their combinations in this setting. 

» Listen now

Dr. Elena Castro

Biomarker-driven management of NSCLC (Link opens in a new window)


Expert-led, multiformat program which will address the individualized management of NSCLC, through education on the detection of NTRK gene fusions, current evidence-based guidelines, and new and emerging therapies. Will also include guidance on integrating shared decision making into your clinical practice, drawing on insights from a patient on how best to communicate.

1.0 AMA PRA Category 1 Credit(s)™

Supported by:
  • Bayer HealthCare Pharmaceuticals Inc.

Further Reading

Factor XI: structure, function and therapeutic inhibition

Open Access Enoxaparin

Arterial and venous thromboembolism is a major medical concern that requires therapeutic anticoagulation in various medical fields to prevent its drastic consequences. Despite significant advances in anticoagulant therapy, thrombosis remains a …

Tolerability and effectiveness of palbociclib in older women with metastatic breast cancer

Open Access Breast Cancer Research

Breast cancer is a common disease among older women, with over 30% of new cases diagnosed in patients aged ≥ 70 years [ 1 ]. Yet, they are still underrepresented in pivotal trials investigating novel therapies [ 2 ]. Furthermore, previous studies …

Comparative Effectiveness of Valoctocogene Roxaparvovec and Prophylactic Factor VIII Replacement in Severe Hemophilia A

Open Access Hemophilia Original Research

Hemophilia A (HA), a rare X-linked recessive bleeding disorder caused by a deficiency of coagulation factor VIII (FVIII) protein [ 1 ], affects approximately 17.1 per 100,000 male individuals worldwide [ 2 ]. Standard of care (SOC) for individuals …

Intramyocardial abscess and endoventricular thrombosis: a complex case

Open Access Endocarditis Case Report

Infective endocarditis (IE) is today a public health problem, as the recent ESC Guidelines have also recalled. Abscesses can be complications of IE and their presence means that the infection is not controlled. We describe the complex case of a …